4.92
price down icon3.91%   -0.20
after-market Handel nachbörslich: 4.92
loading
Schlusskurs vom Vortag:
$5.12
Offen:
$5.12
24-Stunden-Volumen:
506.11K
Relative Volume:
0.56
Marktkapitalisierung:
$438.57M
Einnahmen:
$380.79M
Nettoeinkommen (Verlust:
$49.27M
KGV:
7.0286
EPS:
0.7
Netto-Cashflow:
$10.68M
1W Leistung:
+2.71%
1M Leistung:
-7.52%
6M Leistung:
-6.46%
1J Leistung:
+187.72%
1-Tages-Spanne:
Value
$4.90
$5.121
1-Wochen-Bereich:
Value
$4.705
$5.33
52-Wochen-Spanne:
Value
$1.575
$7.27

Amylyx Pharmaceuticals Inc Stock (AMLX) Company Profile

Name
Firmenname
Amylyx Pharmaceuticals Inc
Name
Telefon
617-683-0917
Name
Adresse
43 THORNDIKE STREET, CAMBRIDGE
Name
Mitarbeiter
123
Name
Twitter
Name
Nächster Verdiensttermin
2025-03-04
Name
Neueste SEC-Einreichungen
Name
AMLX's Discussions on Twitter

Vergleichen Sie AMLX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
AMLX
Amylyx Pharmaceuticals Inc
4.92 426.99M 380.79M 49.27M 10.68M 0.70
Biotechnology icon
ONC
Beone Medicines Ltd Adr
258.27 26.01B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
445.85 114.30B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.3499 41.83M 0 0 0 0.00
Biotechnology icon
VRNA
Verona Pharma Plc Adr
83.98 6.29B 0 -153.72M -103.81M -2.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
484.93 63.90B 14.09B 4.50B 2.96B 39.28

Amylyx Pharmaceuticals Inc Stock (AMLX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-05-30 Eingeleitet TD Cowen Buy
2025-04-07 Hochstufung Mizuho Neutral → Outperform
2024-11-18 Hochstufung Robert W. Baird Neutral → Outperform
2024-10-23 Hochstufung BofA Securities Neutral → Buy
2024-03-18 Herabstufung Mizuho Buy → Neutral
2024-03-11 Herabstufung Leerink Partners Outperform → Market Perform
2024-03-11 Herabstufung Robert W. Baird Outperform → Neutral
2024-03-08 Herabstufung Evercore ISI Outperform → In-line
2024-03-08 Herabstufung Goldman Buy → Neutral
2024-01-03 Eingeleitet Robert W. Baird Outperform
2023-12-12 Eingeleitet Deutsche Bank Buy
2023-07-24 Hochstufung Goldman Neutral → Buy
2023-03-31 Eingeleitet Mizuho Buy
2023-01-05 Eingeleitet BofA Securities Buy
2022-05-25 Eingeleitet Citigroup Buy
2022-04-01 Herabstufung Goldman Buy → Neutral
Alle ansehen

Amylyx Pharmaceuticals Inc Aktie (AMLX) Neueste Nachrichten

pulisher
Jun 03, 2025

Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Shareholders to Inquire about Securities Investigation - ACCESS Newswire

Jun 03, 2025
pulisher
Jun 03, 2025

Amylyx Pharmaceuticals Receives U.S. FDA Fast Track Designation for AMX0114 for the Treatment of Amyotrophic Lateral Sclerosis - BioSpace

Jun 03, 2025
pulisher
Jun 03, 2025

Amylyx gets FDA fast track status for ALS treatment - Seeking Alpha

Jun 03, 2025
pulisher
Jun 03, 2025

Amylyx Pharmaceuticals' Potential ALS Treatment Gets FDA Fast Track Designation - marketscreener.com

Jun 03, 2025
pulisher
Jun 03, 2025

FDA fast tracks Amylyx’s ALS drug candidate AMX0114 By Investing.com - Investing.com Nigeria

Jun 03, 2025
pulisher
Jun 03, 2025

Amylyx (AMLX) Gains FDA Fast Track Status for ALS Treatment | AM - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

FDA fast tracks Amylyx’s ALS drug candidate AMX0114 - Investing.com

Jun 03, 2025
pulisher
Jun 03, 2025

Amylyx (AMLX) Gains FDA Fast Track Status for ALS Treatment | AMLX Stock News - GuruFocus

Jun 03, 2025
pulisher
Jun 02, 2025

DEADLINE ALERT: Bernstein Liebhard LLP Reminds Amylyx Pharmaceuticals, Inc. Investors of Upcoming Deadline - ACCESS Newswire

Jun 02, 2025
pulisher
Jun 02, 2025

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Shares Purchased by Millennium Management LLC - Defense World

Jun 02, 2025
pulisher
Jun 01, 2025

Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Shareholders to Connect - ACCESS Newswire

Jun 01, 2025
pulisher
Jun 01, 2025

Northern Trust Corp Purchases 11,214 Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - Defense World

Jun 01, 2025
pulisher
May 31, 2025

Amylyx Pharmaceuticals (NASDAQ:AMLX) Now Covered by TD Cowen - Defense World

May 31, 2025
pulisher
May 31, 2025

TD Cowen starts Amylyx stock coverage with Buy rating - Investing.com Australia

May 31, 2025
pulisher
May 30, 2025

Amylyx (AMLX) Receives Buy Rating from TD Cowen on Avexitide Pot - GuruFocus

May 30, 2025
pulisher
May 30, 2025

TD Cowen starts Amylyx stock coverage with Buy rating By Investing.com - Investing.com Nigeria

May 30, 2025
pulisher
May 30, 2025

Amylyx (AMLX) Receives Buy Rating from TD Cowen on Avexitide Potential | AMLX Stock News - GuruFocus

May 30, 2025
pulisher
May 30, 2025

Amylyx initiated with a Buy at TD Cowen - TipRanks

May 30, 2025
pulisher
May 29, 2025

Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Investors to Connect - ACCESS Newswire

May 29, 2025
pulisher
May 29, 2025

2025-05-29 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Investors to Connect | NDAQ:AMLX | Press Release - Stockhouse

May 29, 2025
pulisher
May 28, 2025

Amyotrophic lateral Sclerosis Market 2025-2032: Top Trends & - openPR.com

May 28, 2025
pulisher
May 28, 2025

🌐 ALS Treatment Market to Hit $1.04 Billion by 2032 | Driven by New Drug Approvals & Asia-Pacific Expansion - openPR.com

May 28, 2025
pulisher
May 27, 2025

Man Group plc Trims Stock Position in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - Defense World

May 27, 2025
pulisher
May 25, 2025

Bank of America Corp DE Increases Stock Holdings in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - Defense World

May 25, 2025
pulisher
May 25, 2025

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire

May 25, 2025
pulisher
May 24, 2025

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Shares Sold by D. E. Shaw & Co. Inc. - Defense World

May 24, 2025
pulisher
May 22, 2025

Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire

May 22, 2025
pulisher
May 21, 2025

Amylyx Pharmaceuticals to Participate in Upcoming June Investor Conferences - BioSpace

May 21, 2025
pulisher
May 20, 2025

2025-05-20 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Investors to Connect | NDAQ:AMLX | Press Release - Stockhouse

May 20, 2025
pulisher
May 20, 2025

Wall Street Analysts See a 105.22% Upside in Amylyx Pharmaceuticals (AMLX): Can the Stock Really Move This High? - Yahoo Finance

May 20, 2025
pulisher
May 20, 2025

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Receives Consensus Rating of “Buy” from Analysts - Defense World

May 20, 2025
pulisher
May 18, 2025

2025-05-18 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Stockholders to Learn More About the Investigation | NDAQ:AMLX | Press Release - Stockhouse

May 18, 2025
pulisher
May 18, 2025

Dimensional Fund Advisors LP Acquires Shares of 54,114 Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - Defense World

May 18, 2025
pulisher
May 18, 2025

Head-To-Head Survey: Perrigo (NYSE:PRGO) versus Amylyx Pharmaceuticals (NASDAQ:AMLX) - Defense World

May 18, 2025
pulisher
May 16, 2025

Mizuho Boosts Amylyx Pharmaceuticals (NASDAQ:AMLX) Price Target to $8.00 - Defense World

May 16, 2025
pulisher
May 14, 2025

Mizuho Adjusts Price Target on Amylyx Pharmaceuticals to $8 From $7, Maintains Outperform Rating - marketscreener.com

May 14, 2025
pulisher
May 14, 2025

Amylyx (AMLX) Gets Price Target Boost Following Positive Trial Update | AMLX Stock News - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Amylyx price target raised to $8 from $7 at Mizuho - TipRanks

May 14, 2025
pulisher
May 14, 2025

Transcript : Amylyx Pharmaceuticals, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 01 - marketscreener.com

May 14, 2025
pulisher
May 13, 2025

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Investors to Reach Out - ACCESS Newswire

May 13, 2025
pulisher
May 13, 2025

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Q1 2025 Earnings Call Transcript - Insider Monkey

May 13, 2025
pulisher
May 13, 2025

Hsbc Holdings PLC Lowers Holdings in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - Defense World

May 13, 2025
pulisher
May 13, 2025

Amylyx Pharmaceuticals’ Earnings Call Highlights Progress and Challenges - TipRanks

May 13, 2025
pulisher
May 12, 2025

AMX0035 shows promise in Wolfram syndrome trial By Investing.com - Investing.com South Africa

May 12, 2025
pulisher
May 12, 2025

AMLX Reports Promising Results from HELIOS Trial for Wolfram Syn - GuruFocus

May 12, 2025
pulisher
May 12, 2025

H.C. Wainwright raises Amylyx stock target to $16 on trial hopes By Investing.com - Investing.com South Africa

May 12, 2025
pulisher
May 12, 2025

H.C. Wainwright raises Amylyx stock target to $16 on trial hopes - Investing.com Australia

May 12, 2025
pulisher
May 12, 2025

Amylyx Pharmaceuticals Announces Positive Long-Term Results from Phase 2 HELIOS Clinical Trial of AMX0035 in People with Wolfram Syndrome - BioSpace

May 12, 2025
pulisher
May 12, 2025

Amylyx Pharmaceuticals Announces Positive Long-Term Results From Phase 2 Helios Clinical Trial Of Amx0035 In People With Wolfram Syndrome - marketscreener.com

May 12, 2025
pulisher
May 12, 2025

AMX0035 shows promise in Wolfram syndrome trial - Investing.com Australia

May 12, 2025
pulisher
May 12, 2025

Barclays PLC Cuts Holdings in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - Defense World

May 12, 2025

Finanzdaten der Amylyx Pharmaceuticals Inc-Aktie (AMLX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$1.16
price up icon 0.00%
$573.50
price down icon 0.54%
$36.08
price up icon 15.90%
$305.31
price up icon 0.51%
$4.75
price up icon 3.70%
$484.93
price down icon 0.60%
Kapitalisierung:     |  Volumen (24h):